Fighting Prostate Cancer's Survival Mechanisms

Dr. Kim Chi (1999 Research Grant)

Cancer cells are extremely adaptable and can mutate to resist treatments. For example, cancer cells make a protein called clusterin which resists hormone therapy, radiation and other treatments. Mutations like clusterin make cancer difficult to treat.

In 1999 we awarded Dr. Kim Chi a grant to study a new clusterin-fighting drug. Called OGX-011, the drug his team developed contains genetically engineered material that inhibits the production of clusterin and leaves cancer cells vulnerable to radiation therapy.

Dr. Chi is now overseeing the clinical development of OGX-011. Early results from 72 patients were positive; the drug inhibited clustern in prostate cancer cells by more than 90 per cent. Phase II testing is now ongoing.



Plaid for Dad


Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Honouring dad this Father’s Day the Canadian way: In plaid

TORONTO, ON – (May 8, 2018) – Plaid replaces business-casual on Friday, June 15 as hundreds of thousands of Canadians don the iconic Canadian attire all to honour dad and end prostate cancer.
More

The Finger – A tried and true method to save lives

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.
More

Landmark study links tumour evolution to prostate cancer severity

Toronto (April 19, 2018) – Findings from Canadian Prostate Cancer Genome Network (CPC-GENE) researchers and their collaborators, published today in Cell, show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumour has evolved.
More


Click here for news archive